Saroja Pharma Industries India Ltd

Saroja Pharma Industries India Limited was originally incorporated as Private Limited, in the name and style of 'Saroja Pharma Industries India Private Limited' on January 14 , 2019 vide Certificate of Incorporation issued by the Registrar of Companies, Mumbai, Maharashtra. Later on, Company was converted into Public Limited Company and due to conversion, name of the Company changed to 'Saroja Pharma Industries India Limited' dated April 18, 2023. Saroja Pharma Industries India Limited was founded in 2019 by Mr. Biju Gopinathan Nair and Mr. Manish Dasharath Kamble, upon becoming a globally integrated and highly regarded pharmaceutical and healthcare company, the two Promoters embarked on a journey to establish their business. In its initial stages, the Company operated as a Private Limited entity, operating with the name 'Saroja Pharma Industries India Private Limited.' During this time, they focused on building a strong foundation and laying the groundwork for their future growth and success. With dedication and strategic planning, they managed to establish a reputable presence in the pharmaceutical industry. Gradually, as Company expanded and gained momentum, the Promoters made a significant decision to convert their business from a Private Limited to a Public Limited, through which the Company was establish. Thus, transformation opened up new avenues for growth, allowing it to access a wider pool of investors and enhance the overall market presence. With the new status as a Public Limited Company, Saroja Pharma Industries India Limited further strengthen position into pharmaceutical and healthcare sectors. Thereafter, the Promoters envisioned leveraging the Company's expanded resources, increased capital formation, and enhanced market reach. Since established, the Company provide service deliverance in chemical trading with the best premium pharmaceutical companies in India and abroad for cost effective human and veterinary medicine. Presently, the Company trade into Active Pharmaceuticals Ingredients (API), Pharma Intermediates, Specialty Chemicals, Intermediates for Pharma trading and Solvents used for pharmaceutical products in human and veterinary medicine. Company launched the IPO by issuing 10,84,800 equity shares of Rs 10 each and raised a fresh issue of 9.11 crores on 5th September 2023. In 2025, Company has increased demand for high value intermediates such as N-[(4S,6S)-6-Methyl-7,7-dioxido-2-sulfamoyl] and Para Nitro Phenol essential for drug synthesis. Growing concerns about antimicrobial resistance (AMR) have lead to tighter restrictions on the use of antibiotics in animals. The Company has expanded consumption demands in the emerging markets for their chain of manufacturing and supply chain networks.